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The biofilm inhibitor Carolacton 
inhibits planktonic growth of 
virulent pneumococci via a 
conserved target
Jannik Donner1, Michael Reck1, Simone Bergmann2, Andreas Kirschning3, Rolf Müller4 & 
Irene Wagner-Döbler1
New antibacterial compounds, preferentially exploiting novel cellular targets, are urgently needed to 
fight the increasing resistance of pathogens against conventional antibiotics. Here we demonstrate that 
Carolacton, a myxobacterial secondary metabolite previously shown to damage Streptococcus mutans 
biofilms, inhibits planktonic growth of Streptococcus pneumoniae TIGR4 and multidrug-resistant clinical 
isolates of serotype 19A at nanomolar concentrations. A Carolacton diastereomer is inactive in both 
streptococci, indicating a highly specific interaction with a conserved cellular target. S. mutans requires 
the eukaryotic-like serine/threonine protein kinase PknB and the cysteine metabolism regulator CysR 
for susceptibility to Carolacton, whereas their homologues are not needed in S. pneumoniae, suggesting 
a specific function for S. mutans biofilms only. A bactericidal effect of Carolacton was observed for 
S. pneumoniae TIGR4, with a reduction of cell numbers by 3 log units. The clinical pneumonia isolate 
Sp49 showed immediate growth arrest and cell lysis, suggesting a bacteriolytic effect of Carolacton. 
Carolacton treatment caused a reduction in membrane potential, but not membrane integrity, and 
transcriptome analysis revealed compensatory reactions of the cell. Our data show that Carolacton 
might have potential for treating pneumococcal infections.
The resistance of pathogens against antibiotics is increasing worldwide1, while the number of new antibiotics in 
the clinical pipeline remains to be low2. As antibiotic treatment often fails against pathogens that have developed 
resistance, it disturbs the human microbiome at the same time3, which has become a major concern. New anti-
bacterial compounds are urgently needed, preferably compounds that act on novel or underexploited cellular 
mechanisms and could be used as a starting point for rational drug design4.
Carolacton is a secondary metabolite produced by the myxobacterium Sorangium cellulosum. It is a mac-
rolide ketocarbonic acid5 that can be synthesised de novo6,7. Carolacton was discovered to cause membrane dam-
age of biofilms of the caries pathogen Streptococcus mutans at nanomolar concentrations and is non-toxic to 
eukaryotic cells8. Dental composite materials incorporating Carolacton maintain a strong in vitro activity against 
S. mutans biofilms while the mechanical properties of the material are not affected9, suggesting that such compos-
ites might be applicable to reduce secondary caries formation. Carolacton has only a weak effect on the growth of 
S. mutans10, but inhibits growth of Streptococcus oralis11 and also of Escherichia coli TolC with a minimal inhibi-
tory concentration (MIC) as low as 0.06 μ g/ml5. Carolacton-treated cultures show increased septum formation, 
elongated cells, and cell chains, suggesting defects in cell division or cell wall synthesis8,10–12. All chemical modifi-
cations of Carolacton tested until now rendered the molecule inactive11. Based on these studies, we hypothesised 
that the primary effect of Carolacton is a disturbance of cell division or cell wall synthesis through a stereospecific 
interaction with a conserved cellular target. Moreover, we hypothesised that the death of S. mutans biofilm cells, 
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which occurs several hours after Carolacton treatment at low pH only10, is a secondary effect that might be unique 
to this species due to the strong acidification of mutans streptococci within mature biofilms13.
To investigate these hypotheses and to understand the mode of action of Carolacton in more detail, we stud-
ied the response of S. pneumoniae to Carolacton and compared it with that of S. mutans. S. pneumoniae is a 
ubiquitous colonizer of the nasopharynx14 whose carriers usually remain asymptomatic. Nevertheless, invasive 
and non-invasive pneumococcal infections account for almost half a million hospitalizations and approximately 
22.000 deaths in the United States annually15. A continuous increase in multidrug resistance (MDR, resistant to 
≥ 3 classes of antimicrobials) is being reported16. Particularly the prevalence of S. pneumoniae strains of serotype 
19A has increased drastically from 5% in the mid-1990’s to up to 48% in 200817. Serotype 19A isolates have the 
highest proportion of MDR and extensively drug resistant strains (XDR, resistant to ≥ 5 classes of antimicrobi-
als)18. Consequently, the search for novel antimicrobial compounds and novel cellular targets remains of crucial 
importance, especially with regard to pneumococci.
In this study, we focused on S. pneumoniae TIGR4 as an extensively characterized strain19. For the first time, 
we report complete growth inhibition of planktonically growing cells. We investigated growth inhibition by 
Carolacton of MDR and XDR clinical isolates of S. pneumoniae classified as serotype 19A. To clarify if S. pneumo-
niae shares the molecular target of Carolacton with S. mutans, we tested its sensitivity against 9-epi-Carolacton. 
This Carolacton derivative has the opposite absolute configuration at C-9, the area of macrolactone formation, 
and is inactive against S. mutans11. Cell death of S. mutans biofilm cells has been shown to be dependent on the 
eukaryotic-like serine/threonine protein kinase (eSTK) PknB10 and the regulator of cysteine metabolism CysR20. 
Therefore, their homologues in S. pneumoniae TIGR4 were deleted and their response to Carolacton determined. 
Finally we investigated the transcriptome, including small regulatory RNAs, of Carolacton-treated cultures of 
S. pneumoniae TIGR4, constructed knock-out mutants of strongly differentially expressed genes and tested 
their susceptibility. Our data demonstrate that Carolacton acts via the same molecular target in S. mutans and 
S. pneumoniae. Death of biofilm cells of S. mutans is a late secondary effect. The fast (within 5 min) and distinct 
transcriptional response to Carolacton treatment represents a compensatory mechanism, since deletion of those 
genes does not render the mutants insensitive to Carolacton. Finally, the inhibition of growth of S. pneumoniae by 
Carolacton shows the characteristics of bactericidal and in some cases even bacteriolytic antibiotics.
Results
Carolacton inhibits growth of S. pneumoniae TIGR4 in planktonic culture. Carolacton (0.25 μ g/ml 
final concentration) was added to cultures of S. pneumoniae TIGR4 prior to the onset of the exponential phase 
(OD600 = 0.15, termed “t0”). Carolacton-treated cultures grew at the same rate as untreated controls for about 2 h, 
after which the OD remained constant or decreased (Fig. 1A), suggesting a bactericidal activity21. The Carolacton-
treated cultures typically reached a maximal OD600 of 0.55–0.60, while the controls grew up to an OD600 of 1.8. A 
maximal inhibition of ~67% could be observed after 9 h of growth. Since S. pneumoniae autolyzes after reaching 
the stationary phase22, final cell densities after 24 h were very low and almost the same in treated and untreated 
cultures. The number of viable cells was determined by counting colony forming units (CFUs). Figure 1B shows 
that after 3 h of Carolacton treatment, the number of CFUs was reduced by 1 log unit (92.4%) and decreased fur-
ther by more than 2 log units (99.4%) after 6 h. Since this decrease in CFUs was not accompanied by a reduction 
in OD600, the data indicate reduced cell viability in the presence of Carolacton. For S. pneumoniae TIGR4, the 
minimal inhibitory concentration (MIC) of Carolacton was 0.06 μ g/ml (Table 1). Cells grown with Carolacton 
showed a more voluminous phenotype and a fraction of the cells showed a moderate but significant increase in 
size (Fig. 1C). On average, cell length increased from 1.62 ± 0.4 μ m to 2.08 ± 0.6 μ m, while cell width increased 
from 0.87 ± 0.12 μ m to 0.94 ± 0.11 μ m. Even a 100-fold increase (0.025–2.5 μ g/ml) of the Carolacton concentra-
tion did not increase the inhibition of growth considerably (Supplementary Fig. S1). This is in full accordance 
with Kunze et al. who reported a concentration-independent effect of Carolacton on death of S. mutans biofilms 
over the same concentration range8.
Carolacton inhibits planktonic growth of S. pneumoniae serotype 19A clinical isolates. To 
investigate the effectiveness of Carolacton treatment on S. pneumoniae strains found in pneumococcal disease, 
three different recent clinical isolates of S. pneumoniae, representing drug resistant serotype 19A strains (Table 2, 
Supplementary Table S1), were subjected to Carolacton susceptibility testing. Isolate Sp49 had been obtained 
from the blood of a septic pneumonia patient and was resistant against two classes of antibiotics. Isolate Sp61 and 
Sp64 were XDR (resistant to ≥ 5 classes of antibiotics); they were isolated from the thorax drainage of a pleuritis 
patient and by swab from an ear canal of a non-symptomatic patient, respectively. The growth of all three clinical 
isolates was inhibited by Carolacton, but to a widely varying extent (Fig. 2). The clinical pneumonia isolate (Sp49) 
was most sensitive and showed a different behaviour from TIGR4: it started to die immediately and after 2 h its 
OD was lower than at t0, suggesting a bacteriolytic effect of Carolacton (Fig. 2A). A maximum inhibition of 94.9% 
could be observed after approximately 6–7 h of growth, this was the same time point at which the control culture 
of Sp49 typically reached its peak (OD600 ~1.2). For the clinical pleuritis isolate (Sp61) and the non-invasive 
mid-ear serotype 19A isolate (Sp64), the period of uninhibited growth was longer than for the TIGR4 strain, and 
they reached higher final culture densities than TIGR4. The pleuritis isolate Sp61 showed a maximal inhibition 
of growth of about 45% after 6 h (Fig. 2B). For the non-invasive mid-ear isolate Sp64, the maximal inhibition was 
less than that detected for the pleuritic isolate, reaching a maximum inhibition of 23%. Moreover, the inhibition 
peak was retarded and observed after 8 h (Fig. 2C). Carolacton had a strong lytic effect on clinical isolate Sp49; the 
MIC value determined for this isolate was ≤ 0.03 μ g/ml and thus lower than for TIGR4. Drug-resistant isolates 
Sp61 and Sp64, in contrast, were highly tolerant of Carolacton and were only inhibited at 64 μ g/ml Carolacton 
(Table 1). These results indicate that Carolacton inhibits growth of clinical S. pneumoniae isolates with varying 
efficiency. The degree of inhibition was not affected by the change of serotype from TIGR4 (serotype 4) to the 
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clinical isolates (serotype 19A). Interestingly, growth inhibition was weaker in the pleuritis isolate Sp61 and in 
the non-invasive isolate Sp64, which elicit multiple resistances to antibiotics compared to the pneumonia isolate.
The interaction of Carolacton with its cellular target is highly stereo-specific. The Carolacton 
derivative 9(R)-Carolacton (epi-Carolacton) is a diastereomer of Carolacton exhibiting an inversion at C–9 
[(S)→ (R)] (Fig. 3A). Although the structural changes are minute, epi-Carolacton is biologically inactive against 
S. mutans in biofilms11. Likewise, 0.25 μ g/ml epi-Carolacton, a concentration which is generally applied in our 
growth experiments with streptococci, did not inhibit growth of S. pneumoniae TIGR4 (Fig. 3B). Thus the inter-
action between Carolacton and its molecular target must be highly specific with respect to the stereochemistry 
Figure 1. Treatment with Carolacton inhibits growth of S. pneumoniae TIGR4 and affects cell count and 
cell size. (A) The growth curve indicates a growth inhibition of planktonically growing cells of S. pneumoniae 
TIGR4 by Carolacton at a final concentration of 0.25 μ g/ml. The start OD600 is indicated by a solid horizontal 
line. Depicted is the average inhibition from three independent experiments (± standard deviation). 
(B) Determination of viable cell numbers by plating for colony counts. The cell number was determined 
after plating serial dilutions and counting the CFU. (+ ) 0.25 μ g/ml Carolacton and (− ) control. Data are 
representative for at least three biologically independent experiments (± s.d.). P value: * * * = < 0.001; Mann-
Whitney U. (C) Cell length distribution of cells grown with 0.25 μ g/ml Carolacton for 3 h. A length of ≥ 3 μ m 
was only observed for treated cells (red box). In the microscope image, elongated cells are indicated by arrows, 
a cell showing a bulky and voluminous morphology is marked by an asterisk (* ). The average cell length (L) 
and width (W) with standard deviations are shown for n cells from three independent experiments. Scale bar: 
2.5 μ m. Changes in L and W were statistically significant for P < 0.05 as determined by non-parametric Mann-
Whitney-U test; P(L) < 0.001, P(W) = 0.011.
Strain Carolacton (μg/ml)
TIGR4 0.06
Sp49 (NRZ:3198/36486) ≤ 0.03
Sp61 (NRZ:3364/39533) 64
Sp64 (NRZ:3066/35051) 64
Table 1.  Minimal inhibitory concentration (MIC) of Carolacton against planktonically growing  
S. pneumoniae strains.
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at position 9 of the molecule, heavily influencing the topology of the macrocycle. Due to the stereospecificity of 
this interaction we suggest that the cellular target of Carolacton is likely to be identical between S. mutans and 
S. pneumoniae, in spite of the differences of their physiological responses.
The serine/threonine protein kinase StkP and the regulator CysR are not required for growth 
inhibition by Carolacton. Gene deletion of the signalling kinase PknB induces Carolacton resistance 
of S. mutans biofilms10. The S. pneumoniae genome encodes stkP (sp_1732) as corresponding homologue to 
S. mutans pknB. Therefore, the role of the homologue of PknB in S. pneumoniae, StkP, in Carolacton susceptibility 
of S. pneumoniae TIGR4 was tested. Since the molecular target of Carolacton appears to be highly conserved in 
those two organisms, this analysis will clarify whether a bacterial eukaryotic-like serine/threonine protein kinase 
(eSTK) is the direct molecular target of Carolacton. Due to the strong indications of eSTKs as the primary target 
of Carolacton10, in addition to PCR amplification and DNA-sequencing, the absence of the StkP protein in the 
Δ stkP isogenic mutant was confirmed by immunoblotting using polyclonal anti-StkP antibodies23 (Fig. 4A). The 
StkP deletion strain showed formation of elongated cells and multiple unconstricted septa, as reported previ-
ously23. Its growth was highly impaired; nevertheless, Carolacton treatment led to growth inhibition (Fig. 4B). 
The data show that the Δ stkP TIGR4 strain is susceptible to Carolacton, which is in sharp contrast to the findings 
described for S. mutans10.
Deletion of the cysteine metabolism regulator CysR also resulted in a Carolacton-insensitive mutant 
in S. mutans20. The CysR homologue (SP_0927) was deleted in S. pneumoniae and tested for susceptibility to 
Carolacton. Similar to the Δ stkP strain, growth of the Δ cysR mutant was strongly inhibited by Carolacton 
(Fig. 4C). Thus, the pneumococcal homologues to both proteins mediating the susceptibility to Carolacton in 
S. mutans, StkP and CysR, are most likely not directly involved in the Carolacton response in S. pneumoniae, in 
spite of the presumably conserved molecular target of Carolacton in those two species. We conclude that PknB 
and CysR are involved in the mechanisms of membrane damage at low pH in S. mutans, which is a late secondary 
response to Carolacton treatment. In order to confirm this hypothesis, the effect of Carolacton on membrane 
integrity and membrane potential of S. pneumoniae TIGR4 was analysed.
Effect of Carolacton on cytoplasmic membrane integrity and membrane potential in S. pneumoniae. 
For S. mutans it has been reported that Carolacton leads to death of biofilm cells at low pH by disturbing the 
integrity of the plasma membrane and thereby causing leakage of cytoplasmic proteins and DNA10. Membrane 
damage of S. pneumoniae cells was similarly determined by LIVE/DEAD staining during exponential and sta-
tionary phase, 3 h and 6 h after addition of Carolacton, respectively. Heat-killed S. pneumoniae cells were included 
as a control and a calibration curve was recorded using flow cytometry (Supplementary Fig. S2). No indica-
tion of S. pneumoniae cell death by Carolacton treatment was detected (Supplementary Fig. S3). Controls and 
Carolacton-treated cultures both contained a maximum of 14% cells with defective plasma membranes (Fig. 5A).
We then used staining with the fluorescent dye 3,3-Diethyloxacarbocyanine iodide (DiOC2(3)) to determine 
changes in the MP upon Carolacton treatment. Since the measured fluorescence intensities are directly influenced 
by the size of the stained particles, and Carolacton treatment affects the cell size, a size-independent ratiometric 
technique was applied24. Carolacton treatment caused a time-dependent depolarization of the membrane poten-
tial (Fig. 5B, Supplementary Fig. S4). Approximately 48% of the cells showed a membrane depolarization, indi-
cated by a reduction of the red/green fluorescent ratio, after 3 h. Membrane depolarization continued during the 
next 3 h, though not as fast as during the first time interval. After 6 h, the red/green fluorescent ratio dropped to 
~34% of that measured for an exponentially growing control after 3 h, and was reduced to ~56% when compared 
to the control at the same time point. These results indicate a Carolacton-dependent disturbance of the membrane 
potential during growth that is not the result of a porous plasma membrane.
Strain/plasmid Relevant genotype/serotype Description Reference
Streptococcus pneumoniae
 TIGR4 (ATCC BAA-334) encapsulated serotype 4 wild type 19
 JD01 TIGR4 sp_1732::ermR Δ stkP strain This work
 JD02 TIGR4 sp_0927::ermR Δ cysR strain This work
 JD03 TIGR4 sp_0119::ermR Δ sp_0119 strain This work
 JD04 TIGR4 sp_0120::ermR Δ gidA strain This work
 JD05 TIGR4 sp_0119-sp_0120::ermR Δ sp_0119/Δ gidA strain This work
Clinical isolates
 Sp49 serotype 19A pneumonia/sepsis isolate M. van der Linden, NRZ Aachen
 Sp61 serotype 19A pleuritis isolate M. van der Linden, NRZ Aachen
 Sp64 serotype 19A mid-ear isolate M. van der Linden, NRZ Aachen
Plasmid
 pALN122 ermR 58
Table 2.  Bacterial strains, clinical isolates and plasmids used in this study.
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Transcriptional response of S. pneumoniae TIGR4 to Carolacton. We analysed the transcriptome 
of S. pneumoniae TIGR4 cells growing with Carolacton starting 5 min after addition of the drug, until 3 h after 
Carolacton addition. Total RNA was fractionated into two size classes: > 200 nt and ≤ 200 nt, and differential 
regulation of mRNAs (30–4776 nt), small RNAs (37–486 nt) and tRNAs (71–90 nt) was assessed individually. We 
noted a high number of reads for the previously identified housekeeping sRNAs 6S RNA (194 nt)25 and RNase 
P (391 nt)/tmRNA (348 nt)26,27 in the samples containing small transcripts (≤ 200 nt) or in the samples contain-
ing large transcripts (> 200 nt), respectively, confirming the applicability of our sequencing approach for reliable 
separation of transcripts according to length (Supplementary Dataset 1). Since differential transcription after 
Carolacton treatment was exclusively limited to the later time points (t120/t180), we chose to only sequence three 
time points (t0, t5 and t180) for analysis of short small RNAs/tRNAs. The RNA-seq data of biological replicates 
showed a very high Pearson correlation between 0.93 for small regulatory RNAs/tRNAs and 0.99 for large regu-
latory RNAs/mRNAs.
None of the 58 tRNAs of S. pneumoniae TIGR4 were significantly differentially expressed after Carolacton 
treatment (Supplementary Fig. S5, Supplementary Dataset 1).
Figure 2. Activity of Carolacton against S. pneumoniae clinical isolates of serotype 19A. Growth inhibition 
of pneumococcal clinical isolates Sp49 (pneumonia/sepsis isolate, (A)), Sp61 (pleuritis isolate, (B)) and Sp64 
(mid ear isolate, (C)) in THBY. Carolacton was added at a final concentration of 0.25 μ g/ml prior to the onset 
of exponential growth at an OD600 of 0.15. The start OD600 is indicated by a solid horizontal line. The growth 
curves show the average inhibition calculated from three independent experiments (± s.d.).
www.nature.com/scientificreports/
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Differential transcription of small regulatory RNAs. A total number of 181 known small sRNAs 
(≤ 200 nt) and 21 known long sRNAs (> 200 nt) were analysed. Transcription of the vast majority of sRNAs was 
confirmed by obtaining high read counts after mapping (Supplementary Dataset 1). Seven small sRNAs were 
differentially transcribed at t180 only (Supplementary Fig. S5). The highest upregulated small sRNA trn0057 
(log2FC~3.9) is located downstream of the sp_0119-sp_0120 operon and its function is unknown. Ten long sRNAs 
were differentially regulated at t120 and t180 (Supplementary Fig. S5) of which only two (R12 and F20) have been 
investigated and were shown to be important for virulence in mice28.
Differential transcription of mRNAs. RNA-seq data was analysed for differential expression of 1985 large 
(> 200 nt) and 120 small (≤ 200 nt) transcripts of S. pneumoniae TIGR4, accounting for 2105 protein-coding genes 
(Supplementary Dataset 2). Carolacton caused a maximum of differential gene expression after 120 and 180 min. 
Overall, only 1.9% of the 2105 protein encoding genes were differentially transcribed (log2FC ≥ ± 2, FDR < 0.01) 
(Supplementary Fig. S6).
Two transcripts smaller than 200 nt were differentially regulated, a type II DNA modification methyltrans-
ferase (sp_0569) and the 50S ribosomal protein L28 (sp_0441) (Supplementary Fig. S5). 39 transcripts larger than 
200 nt were strongly differentially expressed (log2FC ≥ ± 2 and FDR < 0.01 for at least one time point) (Fig. 6), 26 
of which are encoded within 7 operons on the TIGR4 chromosome (Table 3). Differential expression of sp_0119 
and sp_0120 was detected already 5 min after addition of Carolacton and continued to increase during the exper-
iment to a final log2FC of 4.4 and 4.3 after 180 min, respectively. Sp_0119 codes for a MutT/Nudix family protein 
and sp_0120 encodes the glucose-inhibited division protein A (GidA).
Influence of sp_0119 and sp_0120 on susceptibility of S. pneumoniae TIGR4 to Carolacton. 
Since the gene products of both sp_0119 and sp_0120 are involved in central cellular processes we wondered 
whether an uncontrolled transcriptional upregulation of this operon could cause the growth inhibitory effect of 
Carolacton. Therefore, single deletion mutants of sp_0119 and sp_0120 and a Δ sp_0119-sp_0120 double mutant 
were constructed in S. pneumoniae TIGR4. Growth of all three mutant strains was still significantly inhibited by 
Carolacton treatment (Supplementary Fig. S7).
Figure 3. Effect of epi-Carolacton on growth of S. pneumoniae TIGR4. (A) Chemical structures of native 
9(S)-Carolacton (top) and the 9(R)-epimer (epi-Carolacton, bottom) obtained by total synthesis. (B) Cells were 
treated with epi-Carolacton (black dots) at a final concentration of 0.25 μ g/ml at an OD600 of 0.15. As control, 
pneumococci were cultivated with an equivalent volume of solvent (DMSO, white dots). The experiment was 
repeated independently at least three times.
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Comparison of the transcriptome of S. mutans UA159 and S. pneumoniae TIGR4 in response 
to Carolacton. Until now, the only other organism for which the influence of Carolacton has been studied 
in more detail is the human oral pathogen S. mutans. Therefore, the RNA-seq data obtained in this study were 
compared to microarray data previously obtained for Carolacton-treated S. mutans biofilm cells10. 22.8% of all 
genes were differentially transcribed at 180 min in S. pneumoniae at a log2FC of ≥ ± 0.8 (Supplementary Fig. S6), 
which had previously been used for S. mutans10. At this cut-off, the effect of Carolacton was highly pleiotropic. 
Supplementary Fig. S8 shows a direct comparison between log2FC of the most strongly differentially expressed 
genes in S. mutans compared to their homologues in S. pneumoniae. Overall, the patterns of transcriptional 
changes were similar for some, but not all genes, and the timing and extent of the responses shows differences 
(Supplementary Fig. S8). For example, upregulation of the ComDE two-component system (TCS) for genetic 
competence is observed in both species, but stronger and earlier in S. pneumoniae, and might represent a gen-
eral stress response29. The most conspicuous transcriptional response in S. mutans was the instantaneous strong 
upregulation of genes for pyrimidine biosynthesis. In S. pneumoniae, transcription of these genes showed a differ-
ent pattern, indicating that their regulation in S. mutans might be related to the membrane damage occurring at 
later stages of biofilm growth. In S. mutans, downregulation of sortase A was observed. In S. pneumoniae TIGR4, 
neither sortase A (srtA, sp_1218) nor its three sortase paralogs (srtBCD, sp_0466-sp_0468)30 were differentially 
transcribed. Also in contrast to S. mutans, the VicKRX TCS was not differentially expressed upon Carolacton 
Figure 4. Growth inhibition of S. pneumoniae TIGR4ΔstkP and TIGR4ΔcysR by treatment with 
Carolacton. (A) Immunoblot analysis with StkP-specific antibodies of S. pneumoniae TIGR4 and TIGR4Δ 
stkP confirms absence of StkP-expression in the TIGR4Δ stkP deletion mutant. Pneumococcal α -enolase was 
detected with specific antibodies as loading control. Presented are two parts of the same blot treated with 
different primary antibodies. (B) Growth inhibition of a TIGR4Δ stkP mutant (solid lines) is plotted after 
addition of 0.25 μ g/ml Carolacton (black dots) and without Carolacton as control (white dots). (C) Inhibition 
of a planktonically growing TIGR4Δ cysR mutant with (black dots) and without (white dots) Carolacton. 
Inhibition of the TIGR4 wild type strain (dotted lines), used as controls during both assays (Carolacton-
treated = black triangles, control = white triangles), is displayed as a semi-transparent plot in (A) and (B). All 
growth curves present the average of three independent biological replicates.
www.nature.com/scientificreports/
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treatment in S. pneumoniae. Consequently, the VicKRX regulon also showed a different pattern: only transcripts 
of the cell shape proteins MreC and MreD were upregulated, although earlier and stronger than in S. mutans. In 
S. mutans, cell wall metabolism-related genes were upregulated, while the respective homologues in S. pneumo-
niae TIGR4 were not significantly differentially expressed.
Interestingly, the gidA homologue of S. mutans (smu_2141) was among the most strongly upregulated tran-
scripts like in S. pneumoniae, although its upregulation was weaker and occurred later than in the pneumococcus 
(Supplementary Fig. S8).
Taken together, the transcriptional response of S. mutans and S. pneumoniae to Carolacton appears to be a 
pleiotropic stress response, different between species, and not a specific and focused transcriptional response as 
assumed after studies with S. mutans before10.
Discussion
For the first time we report on the physiological effect of Carolacton on the clinically relevant human pathogen 
S. pneumoniae. Growth of planktonic cultures of S. pneumoniae is already inhibited by Carolacton at a concen-
tration as low as 0.025 μ g/ml (Supplementary Fig. S1). Growth inhibition starts about 2 h after application of 
the drug; at later time points, the optical density remains constant, but the number of viable cells continues to 
decrease. Such behaviour is typically observed when treating pneumococci with bactericidal antibiotics21. Growth 
inhibition by Carolacton is concentration-independent, which could indicate that the primary cellular target of 
Carolacton is easily saturated and thus of low abundance in cells.
Here we show that growth inhibition by Carolacton occurs for clinical isolates as well as for the virulent 
laboratory strain TIGR4 and thus appears to be independent of the serotype. Interestingly, the susceptibility to 
Carolacton was related to the drug resistance of the pathogen. The sepsis isolate Sp49 (which is resistant to two 
classes of antibiotics only) was instantly killed by Carolacton, while the multidrug-resistant isolates Sp61 and 
Sp64 were inhibited to a lower degree than the TIGR4 strain. Accordingly, also the MIC values of Carolacton dif-
fered notably between S. pneumoniae TIGR4 and among the clinical isolates. Carolacton has a potent inhibitory 
effect on S. pneumoniae TIGR4 and Sp49 with MIC values in the range of MICs of classical antibiotics used for 
the therapy of pneumococcal disease, such as e.g. ampicillin, clarithromycin or rifampicin31. The exact MIC of 
Sp49 remains to be determined and could be even lower than 0.03 μ g/ml. Multidrug-resistant isolates Sp61 and 
Sp64 can tolerate and grow in the presence of high concentrations of Carolacton. Multidrug resistance is often 
mediated by increased expression or activity of multidrug efflux pumps. Sp61 and Sp64 are resistant to mac-
rolides (clarithromycin, telithromycin)32 and fluoroquinolones (levofloxacin)33, which is mediated by efflux in 
the pneumococcus. Carolacton is structurally similar to the macrolide class of natural compounds and might be 
exported in a similar way. Unspecific efflux of Carolacton over time, as a by-product of resistance to macrolides 
and fluoroquinolones, could explain why the MICs of Sp61 and Sp64 are much higher than that of S. pneumo-
niae TIGR4. This is in accordance with the observation that E. coli is insensitive to Carolacton, but the growth of 
E. coli TolC, which lacks a multidrug efflux pump, is completely inhibited5. These findings are important for future 
Figure 5. Effect of Carolacton-treatment on the membrane integrity and membrane potential of S. 
pneumoniae TIGR4. (A) Cells grown with 0.25 μ g/ml Carolacton (+ ) and controls (− ) were stained with Syto 
9/PI and analysed using flow cytometry as exemplified in Fig. S8. Error bars of stained heat-killed controls 
(red bars) are not visible, as continuously more than 99.9% of all heat-treated cells were killed and emitted red 
fluorescence. (B) Changes in membrane potential were quantified by flow cytometric analysis of DiOC2(3)-
stained planktonic cells. The relative membrane potential was calculated ratiometrically. Analyses were carried 
out with 30 μ M DiOC2(3). Heat-killed cells served as a control for fully depolarized cells. The bar charts present 
the average of three biological replicates (± s.d.). P value: n.s. = > 0.05; * * = < 0.01; * * * = < 0.001; two-tailed 
Student’s t-test.
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development of the compound and potential clinical applications. For example, Carolacton could be used syner-
gistically with structurally unrelated non-macrolide antibiotics.
A Carolacton derivative with an inverted stereocentre at C-9 (epi-Carolacton) was completely inactive against 
both S. mutans and S. pneumoniae, as well as against several oral streptococci11. All other chemical modifications 
of the side-chain or the lactone ring tested so far were also inactive11. This indicates a highly stereospecific inter-
action of Carolacton with its molecular target and led us to hypothesise that the target could be highly conserved 
and shared between S. pneumoniae and S. mutans. It appears unlikely that a switch of the stereochemistry at C-9 
could completely abolish interaction with multiple less conserved targets in both species. If Carolacton would 
interact with several weakly conserved targets, we would expect a remaining activity of epi-Carolacton in one 
of the tested species, which is absent as shown here and previously11. A pattern similar to the one described 
for epi-Carolacton here was found for the antibiotic fosfomycin, which targets the conserved bacterial cell wall 
hydrolase MurA34, but its stereoisomer lacks antimicrobial activity35. Consequently we investigated the roles of 
PknB and CysR, which both had been shown to be essential for the damage of biofilm cells of S. mutans at low 
pH10,20, for Carolacton susceptibility in S. pneumoniae. Our data indicate that neither StkP nor CysR are required 
for susceptibility of S. pneumoniae to Carolacton and they thus cannot be its molecular target if this is conserved 
in both streptococci. Another indication that Carolacton acts independently of StkP is the potent activity of 
Carolacton against E. coli TolC, as E. coli does not possess StkP homologues36. StkP and CysR are apparently 
exclusively important for S. mutans at low pH in mature biofilms, which is a unique environment fundamentally 
different from planktonically growing S. pneumoniae cultures.
Figure 6. Differentially regulated mRNAs in S. pneumoniae TIGR4 upon treatment with Carolacton. The 
heat map illustrates the 39 most differentially expressed genes (mRNA > 200 nt) after addition of Carolacton 
(0.25 μ g/ml). The cut-off for differentially regulated genes was set at log2FC ≥ ± 2 and FDR < 0.01 for at least 
one sample during the time course. RNA-seq data was analysed using Rockhopper and the edgeR package for R. 
The heat map was constructed using the R package gplots. Main operon structures are indicated by vertical lines 
on the left. Information on encoded proteins and their involvement in biological pathways were obtained from 
KEGG ORTHOLOGY or KEGG BRITE databases.
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As a possible mode of action of Carolacton, Reck et al. proposed a disturbance of cell wall regulatory processes, 
resulting in plasma membrane damage and leakage of cytoplasmic content at a low pH10. Plasma membrane 
Locus tag Gene product Gene symbol log2FCa FDR
Galactose uptake (PTS)/N-acetylgalactosamine uptake (PTS)/Protein export
 sp_0324 PTS system transporter subunit IIC 4.68 7.52E-91
 sp_0325 PTS system transporter subunit IID 4.56 5.10E-123
 sp_0322 glucuronyl hydrolase 4.73 2.58E-100
 sp_0327 hypothetical protein 4.41 5.05E-74
 sp_0323 PTS system transporter subunit IIB 4.80 2.75E-95
 sp_0326 preprotein translocase subunit yajC 4.55 5.11E-74
 sp_0321 PTS system transporter subunit IIA 4.96 6.23E-89
Carbon metabolism/Pentose phosphate pathway
 sp_0318 carbohydrate kinase 4.13 1.30E-67
 sp_0320 gluconate 5-dehydrogenase 4.08 1.82E-78
 sp_0317 4-hydroxy-2-oxoglutarate aldolase/2-dehydro-3-deoxyphosphogluconate aldolase 3.82 6.60E-64
 sp_0319 hypothetical protein 3.88 4.69E-72
Protein degradation
 sp_0338 ATP-dependent Clp protease, ATP-binding subunit 3.73 4.09E-67
MutT/nudix family protein/transfer RNA biogenesis
 sp_0119 MutT/nudix family protein 4.44 2.57E-67
 sp_0120 tRNA uridine 5-carboxymethylaminomethyl modification protein gidA 4.33 1.35E-50
Phosphate (Pi) uptake (ABC transporter)
 sp_2087 phosphate transporter ATP-binding protein pstB 2.96 1.16E-45
 sp_2086 phosphate ABC transporter permease pstA 2.97 1.34E-42
 sp_2084 phosphate ABC transporter permease pstS 2.89 2.78E-38
 sp_2085 phosphate ABC transporter substrate-binding protein pstC 2.96 2.78E-33
 sp_2088 phosphate transport system regulatory protein phoU 3.19 5.26E-42
 sp_0789 conserved hypothetical protein 2.64 2.13E-37
 sp_0790 conserved hypothetical protein 2.58 2.77E-44
 sp_0018 hypothetical protein 2.10 1.13E-24
Genetic competence
 sp_2207 competence protein comFC 2.21 2.18E-05
 sp_2208 helicase comFA 2.22 3.04E-09
 sp_1793 hypothetical protein 2.17 9.19E-32
 sp_1777 hypothetical protein 2.22 2.46E-25
 sp_2013 hypothetical protein 2.13 4.64E-31
Nicotinate and nicotinamide metabolism
 sp_2015 IS630-Spn1, transposase Orf1 2.74 2.48E-40
 sp_2016 nicotinate-nucleotide pyrophosphorylase 2.60 1.07E-46
 sp_0539 bacteriocin blpM 2.59 1.38E-04
Starch and sucrose metabolism
 sp_1722 PTS system IIABC components 0.87 6.04E-04
 sp_1314 IS66 family element, Orf1 − 3.11 7.89E-03
 sp_1803 hypothetical protein − 1.35 3.02E-09
Central carbon/lipid metabolism
 sp_0252 fructose-6-phosphate aldolase − 2.34 4.59E-06
 sp_0253 glycerol dehydrogenase − 2.57 2.21E-07
 sp_0251 formate acetyltransferase − 2.29 8.60E-06
Cellobiose uptake (PTS)
 sp_0248 PTS system transporter subunit IIA − 2.30 8.11E-05
 sp_0250 PTS system transporter subunit IIC − 2.28 1.85E-05
 sp_0249 PTS system transporter subunit IIB − 2.42 4.79E-05
Table 3. Summary of the most differentially expressed genes upon growth of S. pneumoniae TIGR4 with 
Carolacton for 180 min. Horizontal lines indicate separation of transcriptional units. acut-off: log2FC≥ 2 or  
≤ − 2 at one point during the time course.
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damage is usually paralleled by a loss of membrane potential (MP)37. Treatment with antimicrobial agents such 
as streptomycin, reutericyclin38 or ampicillin37 can decrease the MP and thereby interfere with the localization of 
cell division proteins39. By fluorescent staining of Carolacton-treated cells with DiOC2(3), we detected a continu-
ous decrease in MP over time. When assessing the integrity of the plasma membrane, as a possible cause for MP 
reduction, no damage could be detected. This is in agreement with Kunze et al. who reported no changes in LIVE/
DEAD-stained S. mutans cells during planktonic growth with Carolacton8. Thus, Carolacton treatment leaves the 
plasma membrane intact in both S. mutans and S. pneumoniae during planktonic growth.
To identify components of a possible conserved response in S. mutans and S. pneumoniae, RNA-sequencing 
was carried out. Among differentially regulated sRNAs, sspn1731.1 and sspn1732.1 are strongly downregulated at 
late time points. Both contain a T-box motif that is known to stimulate anti-termination of the tyrS gene in Bacillus 
subtilis by interaction with the acceptor end of tRNA(Tyr)40. T-box leader sequences of non-coding RNAs are part 
of a negative feedback loop controlling expression of aminoacyl-tRNA synthetase genes41 and components of 
the amino acid biosynthesis machinery42. Downregulation of sspn1731.1 and sspn1732.1 may present another 
compensatory mechanism to Carolacton by increasing expression, for example of aminoacyl-tRNA-synthetases. 
Among differentially regulated mRNAs, an immediate strong upregulation of the sp_0119-sp_0120 operon was 
identified. Both encoded proteins have a global regulatory role in S. pneumoniae. The sp_0119 gene encodes 
a MutT/Nudix family-like protein. A homologous protein in E. coli (MutT) functions as an anti-mutator pro-
tein, by maintaining replication fidelity through hydrolysis of mutagenic 8-oxo-dGTP43. Other MutT/Nudix 
family-like proteins in E. coli similarly protect the cell by degradation of toxic nucleotide derivatives44 and have 
been described as “housecleaning” enzymes45. Thus, it can be assumed that SP_0119 likewise plays a role in 
protecting the pneumococcus by detoxification of harmful metabolites. GidA (SP_0120) is a highly conserved 
protein; homologues are present in Proteobacteria and Firmicutes and influence protein biosynthesis by altering 
mRNA codon recognition through modification of tRNAs at the wobble position46. GidA modulates the virulence 
of a large number of pathogens47. Consequently, a Salmonella gidA mutant strain is currently being investigated 
for use in a live-attenuated vaccine48. As an important virulence factor, also in streptococci49, it is conceivable that 
by altering the transcription of gidA, Carolacton may also interfere with virulence of S. pneumoniae. Expression 
of virulence factors is tightly controlled in group A streptococci50 and upregulated transcription of virulence 
factors can have a negative effect on pathogenicity, as shown for Listeria monocytogenes51. The investigation of 
compounds that are aiming at virulence factors in order to render pathogens harmless, instead of targeting essen-
tial cellular components, hold enormous possibilities52. The use of anti-virulence drugs could even counteract 
resistance development in bacteria altogether53. If S. pneumoniae cells show an altered virulence after treatment 
with Carolacton needs to be explored further.
Growth of single and double deletion mutants of sp_0119 and sp_0120 was still impaired by Carolacton, 
thus neither SP_0119 nor SP_0120 qualify as its molecular target. We hypothesise that these proteins mediate a 
compensatory response to Carolacton treatment. This is further confirmed by comparison of the transcriptional 
response of S. mutans and S. pneumoniae, which suggests that these responses likely show species-specific stress 
reactions or compensatory mechanisms and indicate that the effect of Carolacton cannot be compensated by 
differential regulation of a single specific gene set. For example, competence development, e.g. by upregulating 
transcription of comDE, is a direct reaction to stress in bacteria, such as streptococci, that lack a classical SOS 
response54. An upregulation of the VicKRX operon and VicKRX-regulated genes, as seen in S. mutans, possibly 
presents a direct response to disturbance of cell wall homeostasis55. The proteins MreC and MreD are located 
at the equators and septa of dividing S. pneumoniae cells and direct peripheral peptidoglycan synthesis56. Their 
increased transcription after Carolacton treatment could be interpreted as an attempt to compensate defects in 
peptidoglycan synthesis and cell division.
The data show that Carolacton holds promise as a bactericidal antibiotic. The extent of growth inhibition 
observed after Carolacton treatment in S. pneumoniae is variable, does not depend on the serotype and can even 
be bacteriolytic. This calls for further investigation of the primary mode of action of Carolacton and demonstrates 
the importance to discover the direct molecular target as a pre-requisite for rational drug design.
Methods
Additional methods can be found in the Supplementary Information.
Bacterial strains and growth conditions. Bacterial strains used in this study are listed in Table 2. 
S. pneumoniae TIGR4 serotype 4 (ATCC BAA-334), used for growth experiments in liquid medium, was rou-
tinely grown on Columbia blood agar plates containing 5% sheep blood (BD Biosciences) overnight (o/n) at 
37 °C and 5% CO2. Cells were then scraped from plate and used to inoculate Todd-Hewitt-Broth + 1% (w/v) 
yeast extract (THBY, BD Biosciences) liquid medium, starting from an optical density at 600 nm (OD600) of 0.1. 
After the initial culture had reached an OD600 of 0.15, it was split into equal volumes and Carolacton or 9(R) 
epi-Carolacton11 were added to a final concentration of 0.25 μ g/ml, if not stated otherwise. Carolacton was solved 
in methanol and stored 1000-fold concentrated (5.3 mM) in small aliquots in glass vials at − 20 °C in the dark. 
Epi-Carolacton was solved in dimethyl sulfoxide (DMSO) and also stored in concentrated small aliquots (2 mM) 
at − 20 °C in the dark.
Clinical S. pneumoniae isolates and information about clinical background data, serotype and antimicrobial 
susceptibility were obtained from Dr. Mark van der Linden from the National Reference Laboratory (NRZ) on 
Streptococcal Disease in Aachen (Germany). All clinical strains were isolated between 5/2008 and 4/2009. For 
cryo-conservation, S. pneumoniae strains were grown in THBY to early exponential phase (OD600~0.25) and 
immediately frozen at − 80 °C in 10% (v/v) glycerol.
Growth inhibition was calculated as follows:
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Determination of MIC values. S. pneumoniae was grown on Columbia blood agar plates o/n as described 
before. Minimum inhibitory concentration (MIC) values of Carolacton were determined by two-fold serial 
microdilution and incubation at 37 °C and 5% CO2 for 18–20 h, as described for the pneumococcus previously31. 
The dilution range of Carolacton tested was 0.03–128 μ g/ml. The MIC was determined as the lowest concentra-
tion of Carolacton that did not yield visible bacterial growth. The cell number of the initial inoculum was 5 × 105 
CFU/ml as determined by serial dilution and plating. Ampicillin, erythromycin, tetracycline and rifampicin were 
included as controls during MIC determination for S. pneumoniae TIGR4, confirming target MIC values com-
monly reported for susceptible pneumococci31. MICs were confirmed by at least two independent measurements 
(with two replicates).
Construction of gene deletion mutants of S. pneumoniae TIGR4. Construction of gene deletion 
strains in the TIGR4 background was carried out by the Duplicate, cf. end of sentence. PCR ligation mutagenesis 
method, replacing the gene of interest (GOI) with an erythromycin (ermR) resistance cassette, via double homol-
ogous recombination as described previously57. All used enzymes were purchased from New England Biolabs 
(NEB). First, the up- and downstream regions flanking the GOI were amplified using the primer pairs listed in 
Supplementary Table S2, introducing an FseI and an AscI restriction site into the PCR products. The ermR cassette 
was amplified from pALN12258. PCR fragments were digested with the appropriate restriction enzymes and puri-
fied using the QIAquick PCR Purification Kit (Qiagen). 100 ng of all DNA fragments was ligated with T4 DNA 
ligase at 16 °C o/n.
Transformation of S. pneumoniae TIGR4. Transformation of S. pneumoniae was carried out by induction 
of competence by addition of competence stimulating peptide 2 (CSP-2) as described previously57. Briefly, THBY 
(pH 6.8) supplemented with 1 mM CaCl2 and 0.2% (w/v) bovine serum albumin (BSA) was inoculated with 
exponentially growing cells from liquid culture in THBY (OD600~0.5) to an OD600 of 0.005. After reaching the 
early log phase (OD600~0.15), 1 ml culture was harvested by centrifugation and the cells resuspended in 1 ml 
THBY (pH 8.0) supplemented with 1 mM CaCl2, 0.2% (w/v) BSA and 400 ng/ml CSP-2. Transformation was 
achieved by addition of 10 μ l of a ligation mix and static incubation at 37 °C for 2 h. Transformants were selected 
on THBY agar plates containing 0.5 μ g/ml erythromycin. Correct integration was checked by PCR and Sanger 
DNA sequencing.
Verification of the absence of StkP in the TIGR4ΔstkP deletion mutant by immunoblotting. 
In addition to DNA sequencing, the absence of StkP of JD01 was confirmed by immunoblotting. First, a defined 
volume (V[μ l] = 300/OD600) of S. pneumoniae TIGR4 wild type and TIGR4Δ stkP cells in THBY was boiled in 
SDS loading dye (95 °C, 15 min) and separated via 12% (v/v) SDS PAGE according to59. Proteins were blotted to a 
PVDF membrane (Immobilion-P, Milipore) using a semi-dry blotting system (Sigma-Aldrich) and blocked with 
5% (w/v) BSA in TBS-T at room temperature (RT) for 1 h. Incubation with the primary antibody, rabbit anti-StkP, 
was carried out by using a 1:50.000 dilution in 1% (w/v) BSA/TBS-T o/n. Pneumococcal α -enolase (α -eno) 
served as a loading control60. The α –eno antibody was used in a 1:500 dilution in 1% (w/v) BSA/TBS-T at RT o/n. 
Alkaline phosphatase-coupled goat anti-rabbit IgG (Sigma-Aldrich) diluted 1:10 000 in TBS-T was applied for 1 h 
at RT for detection of the primary antibody. Alkaline phosphatase activity was visualized colorimetrically using 
SIGMA FAST BCIP/NBT tablets according to the manufacturer’s instructions (Sigma-Aldrich).
Isolation and enrichment of mRNA. Processing of RNA-seq data is presented in detail in the 
Supplementary Information. Total RNA from was isolated using the miRNeasy mini kit (Qiagen) according to 
the manufacturer’s instructions for separation of small RNA-enriched fractions (≤ 200 nt) and larger transcripts 
(> 200 nt). DNA library generation was carried out using the ScriptSeq™ v2 RNA-Seq Library Preparation Kit 
(epicentre) for long transcripts (> 200 nt), and the TruSeq Small RNA Library Prep Kit (Illumina) for transcripts 
≤ 200 nt. Libraries were sequenced on the Illumina HiSeq 2500 (Illumina) using 50-bp single-end sequencing.
RNA-seq data analysis. Processing of RNA-seq data is described in Supplementary Information. All 
analysed small RNAs are documented in Supplementary Dataset S3. False discovery rate (FDR)-adjusted P val-
ues were calculated according to61. FDR values of < 0.01 were considered significant. For visualization of these 
results heat maps were generated, taking into account only genes that, in addition to a significant FDR, showed a 
log2-fold change (log2FC) of transcription of ≥ ± 2 (or ≥ ± 0.8 for small RNAs) at least at one point during a time 
course. For this, the log2-fold values of transcript abundance obtained in edgeR were used in combination with 
the heatmap. 2 function of the R package gplots (v2.15.0)62. Raw and processed RNA-seq data have been depos-
ited in NCBI’s Gene Expression Omnibus (GEO) database63 and are accessible through GEO Series accession 
number GSE76979.
Fluorescent staining of S. pneumoniae. To detect changes in the membrane potential of S. pneumoniae 
TIGR4 when treated with Carolacton, the bacteria were stained with the f luorescent dye 
3,3-Diethyloxacarbocyanine iodide (DiOC2(3)) (BacLight Bacterial Membrane Potential Kit, Life Technologies). 
For staining with DiOC2(3), cells were diluted from culture to approx. 107 cells/ml and stained with 30 μ M 
DiOC2(3) in the dark for 30 min. In order to assess bacterial membrane integrity, cells were separately co-stained 
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with the fluorescent dyes Syto 9 and propidium iodide (PI) using the LIVE/DEAD BacLight Bacterial Viability 
Kit (Life Technologies).
For Syto 9/PI staining, cells from a culture grown with 0.25 μ g/ml Carolacton and from a control were har-
vested by centrifugation and washed in 0.85% (w/v) NaCl. Approx. 5 × 106 cells/ml were stained with an equal 
volume 2× staining solution (10 μ M Syto 9, 60 μ M PI) at RT in the dark for 30 min. Heat-inactivated cells were 
used as a control in both staining experiments. Heat-killing of cells was achieved by incubation at 80 °C and shak-
ing (1,400 rpm) for 30 min.
Flow cytometric analysis of fluorescently-labelled S. pneumoniae cells. DiOC2(3) and Syto 9/
PI-fluorescently stained cells were analysed in triplicate on a FACSCanto flow cytometer (BD Biosciences) as 
described in the material section of the Supplementary Information.
Microscopy and quantification of cell size. S. pneumoniae TIGR4 cells growing in THBY were washed 
with 0.85% (w/v) NaCl solution and mounted to a microscope slide coated with a thin layer of 1% (w/v) aga-
rose. Phase-contrast microscopic analysis of S. pneumoniae was performed using an Olympus BX60 microscope 
equipped with an Olympus DP50 color camera (5 Mpixel) color view II camera and a 100x magnification oil 
immersion objective. Pictures and measurements were taken with the Olympus cellSens (v1.6) microscopy soft-
ware. The length of pneumococcal cells was measured along the length axis. Cell width was determined as the 
diameter along the equatorial plane, perpendicular to the length axis of the cell.
Quantification of colony forming units. For determination of colony forming units (CFUs), cells were 
treated with Carolacton (0.25 μ g/ml) prior to exponential growth. Ten-fold serial dilutions of cultures were pre-
pared in 0.85% (w/v) NaCl solution (pre-warmed to 37 °C) after 3 h and 6 h of growth. A total volume of 100 μ l 
from each dilution was then plated onto pre-warmed (37 °C) THBY agar plates, which were incubated at 37 °C 
and 5% CO2 o/n.
Statistical analysis. Comparisons between two groups at a single time were performed with unpaired 
two-tailed (non-parametric) Mann-Whitney U test64 or with Student’s t-tests for two-tailed distribution (with 
a critical P value of 0.05). The data were analysed for normality by Shapiro-Wilk test65. Statistical analyses were 
performed with the statistics options of SigmaPlot (v13.0) software (Systat Software Inc.).
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